Rexahn Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch RNN and buy or sell other stocks, ETFs, and their options commission-free!

About RNN

Opus Genetics, Inc. engages in the research and development of ophthalmic biopharmaceutical products. It focuses on developing and commercializing therapies for the treatment of several eye disorders. 

CEO
George Magrath, III, MD
CEOGeorge Magrath, III, MD
Employees
18
Employees18
Headquarters
Durham, North Carolina
HeadquartersDurham, North Carolina
Founded
2018
Founded2018
Employees
18
Employees18

RNN Key Statistics

Market cap
160.76M
Market cap160.76M
Price-Earnings ratio
-6.16
Price-Earnings ratio-6.16
Dividend yield
Dividend yield
Average volume
1.28M
Average volume1.28M
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$5.30
52 Week high$5.30
52 Week low
$0.65
52 Week low$0.65

Stock Snapshot

The current Rexahn Pharmaceuticals(RNN) stock price is $2.30, with a market capitalization of 160.76M. The stock trades at a price-to-earnings (P/E) ratio of -6.16.

During the trading day, Rexahn Pharmaceuticals(RNN) stock saw an opening price of —, a peak of —, and a bottom of —.

Trading activity shows a volume of 0, compared to an average daily volume of 1.28M.

Over the past 52 weeks, Rexahn Pharmaceuticals(RNN) stock has traded between a high of $5.30 and a low of $0.65.

Over the past 52 weeks, Rexahn Pharmaceuticals(RNN) stock has traded between a high of $5.30 and a low of $0.65.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.